Thomas Kurz

Prof. Dr. Thomas Kurz

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NPNicholas J. Porter
Nicholas J. Porter
JOJeremy D. Osko
Jeremy D. Osko
DDDaniela Diedrich
Daniela Diedrich
TKThomas Kurz
Thomas Kurz
JHJacob Hooker
Jacob Hooker
DCDavid W. Christianson
David W. Christianson

19 July 2018 in Blood
Verified
Journal Article
Open access
PDF file
SBSanil Bhatia
Sanil Bhatia
DDDaniela Diedrich
Daniela Diedrich
BFBenedikt Frieg
Benedikt Frieg
HAHeinz Ahlert
Heinz Ahlert
SSStefan Stein
Stefan Stein
JHJulia Hauer
Julia Hauer
Key Points: We have developed a first-in-class C-terminal HSP90 inhibitor (AX) that is effective against TKI-resistant CML and leukemic stem cells. Unlike the majority of HSP90 inhibitors, AX does not induce the HSR as a resistance mechanism.

26 October 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SBSanil Bhatia
Sanil Bhatia
VKViktoria Krieger
Viktoria Krieger
MGMichael Groll
Michael Groll
JOJeremy D. Osko
Jeremy D. Osko
NRNina Reßing
Nina Reßing
FHFinn K. Hansen
Finn K. Hansen

1 July 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FHFinn K. Hansen
Finn K. Hansen
SSSubathdrage D.M. Sumanadasa
Subathdrage D.M. Sumanadasa
KSKatharina Stenzel
Katharina Stenzel
SDSandra Duffy
Sandra Duffy
SMStephan Meister
Stephan Meister
TKThomas Kurz
Thomas Kurz

1 July 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KTKatharine Trenholme
Katharine Trenholme
LMLinda Marek
Linda Marek
SDSandra Duffy
Sandra Duffy
GPGabriele Pradel
Gabriele Pradel
GFGillian Fisher
Gillian Fisher
KAKatherine T. Andrews
Katherine T. Andrews
Therapies to prevent transmission of malaria parasites to the mosquito vector are a vital part of the global malaria elimination agenda. Primaquine is currently the only drug with such activity; however, its use is limited by side effects. The development of transmission-blocking strategies requires an understanding of sexual stage malaria parasite (gametocyte) biology and the identification of new drug leads. Lysine acetylation is an important posttranslational modification involved in regulating eukaryotic gene expression and other essential processes. Interfering with this process with histone deacetylase (HDAC) inhibitors is a validated strategy for cancer and other diseases, including asexual stage malaria parasites. Here we confirm the expression of at least one HDAC protein in Plasmodium falciparum gametocytes and show that histone and nonhistone protein acetylation occurs in this life cycle stage. The activity of the canonical HDAC inhibitors trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA; Vorinostat) and a panel of novel HDAC inhibitors on early/late-stage gametocytes and on gamete formation was examined. Several compounds displayed early/late-stage gametocytocidal activity, with TSA being the most potent (50% inhibitory concentration, 70 to 90 nM). In contrast, no inhibitory activity was observed in P. falciparum gametocyte exflagellation experiments. Gametocytocidal HDAC inhibitors caused hyperacetylation of gametocyte histones, consistent with a mode of action targeting HDAC activity. Our data identify HDAC inhibitors as being among a limited number of compounds that target both asexual and sexual stage malaria parasites, making them a potential new starting point for gametocytocidal drug leads and valuable tools for dissecting gametocyte biology.

13 September 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CBChristoph T. Behrendt
Christoph T. Behrendt
AKAndrea Kunfermann
Andrea Kunfermann
VIVictoria Illarionova
Victoria Illarionova
AMAn Matheeussen
An Matheeussen
MPMiriam Pein
Miriam Pein
TKThomas Kurz
Thomas Kurz